$RDGT

Ridgetech Inc.

Ridgetech is a Cayman Islands holding company that conducts substantially all of its operations in China. It is headquartered in Hangzhou, Zhejiang Province, and focuses on wholesale distribution of pharmaceutical and other healthcare products to retail pharmacies, clinics, trading companies and other vendors. Its products include prescription and over-the-counter drugs, nutritional supplements, traditional Chinese medicine, medical devices, health foods, cosmetics and daily necessities. Ridgetech distributes products offline, primarily to local buyers, and sells online through its own and third-party platforms to customers nationwide. Its wholesale operations include Jiuxin Medicine, which distributes third-party products, and Allright, which also provides online distribution and sales services. The company makes money by selling wholesale products to business customers, including through a supply agreement with Jiuzhou Pharmacy. It no longer operates retail pharmacies or a herb farming business.

No enriched coverage for $RDGT in the last 7 days.

No SEC Form 4 filings for $RDGT in the last 30 days.

See all $RDGT insider activity →
Low

Ridgetech (RDGT) now authorized for 360B shares

Ridgetech Inc. (RDGT) has been authorized for 360 billion shares following a capital reduction and share subdivision. The company's authorized share capital is now $36.01 million, with 360 billion ordinary shares at $0.0001 par value each. The changes were approved by the Cayman Islands Registrar of Companies and became effective on September 2, 2026.

Ridgetech, Inc. Reports Fiscal Year 2026 Financial Results

Ridgetech, Inc. (Nasdaq: RDGT) reported fiscal year 2026 results for the year ended March 31, 2026. Revenue rose 10.2% to $132.16 million, driven by a full year of Allright’s online platform after its Feb. 28, 2025 acquisition. Gross profit increased 23.8% to $4.75 million, but net loss was $1.25 million versus net income $10.20 million a year earlier.

RDGT sentiment & insider activity

Recent RDGT coverage spans corporate actions, insider activity and earnings.

What's driving RDGT

AlphAI scores every news story that mentions RDGT with an AI model for sentiment and relevance, and aggregates insider trades from Ridgetech Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $RDGT

Score

Ridgetech, Inc. Reports Fiscal Year 2026 Financial Results

Ridgetech, Inc. (Nasdaq: RDGT) reported fiscal year 2026 results for the year ended March 31, 2026. Revenue rose 10.2% to $132.16 million, driven by a full year of Allright’s online platform after its Feb. 28, 2025 acquisition. Gross profit increased 23.8% to $4.75 million, but net loss was $1.25 million versus net income $10.20 million a year earlier.

$RDGTMedEarnings

Ridgetech Inc. (RDGT): Financial results for FY2026

Ridgetech Inc. (RDGT) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 Ridgetech, Inc. Reports Fiscal Year 2026 Financial Results HANGZHOU, China, July 31, 2026 /PRNewswire/ -- Ridgetech, Inc. (Nasdaq: RDGT) (“Ridgetech” or the “Company”), a wholesale distributor of pharmaceutical and other healthcare products in China, today announced

Ridgetech Strengthens Pharmaceutical Ecosystem Leadership with Vice-President Role in Zhejiang Biomedical Association

Ridgetech, Inc. (Nasdaq: RDGT) said its wholly owned Zhejiang Jiuxin Medicine Co. was elected a vice-president unit of the Hangzhou Qiantang District Biomedical and Cosmetic High-Quality Development Association, to be inaugurated July 28, 2026. The company links the role to Jiuxin’s full-variety drug traceability code scanning in Zhejiang, following an March 2026 inspection by the Zhejiang Medical Products Administration.

Top Biotech Gainers: ZYBT Skyrockets, ADVB Drops Planned Offering, STIM Gets New CFO, RDGT On Watch

Biotech gainers included Zhengye Biotechnology (ZYBT), up about 1,048% after a Nasdaq bid-price noncompliance notice. Advanced Biomed (ADVB) rose over 70% after withdrawing a planned SEC-registered offering. Neuronetics (STIM) gained after naming a new CFO. Armata Pharmaceuticals (ARMP) advanced on Phase 3 AP-SA02 progress. Other movers: Profusa (PFSA), Ridgetech (RDGT), Turn Therapeutics (TTRX).

Related tickers